KEY TAKEAWAYS
- The study aimed to investigate the behavior and outcomes of C-19 vax in highly vulnerable pts.
- The primary objective was to assess the vax rate in adult ca pts and identify barriers to vax. The secondary objectives were determining factors associated with vax acceptance and hesitancy and identifying C-19 vax side effects.
- The study found that most cancer pts tolerated the C-19 vax well, prior infection decreased uptake, and had no notable effect on ca outcomes.
Cancer (ca) patients (pts) are at high risk for severe COVID-19 (C-19) but were largely excluded from vaccine (vax) trials.
Researchers aimed to study the behavior and outcomes of C-19 vaccination in highly vulnerable ca pts.
The study included adult ca pts aged 18-89 who were randomly surveyed via telephone. Data on ca type and therapy were extracted from patients’ medical records. The survey covered C-19 disease status, vaccination status (vax+ or vax–), side effects, impact on ca treatment, and progression. The study’s primary objectives were to assess vaccination rates and identify barriers among adult ca pts. Secondary objectives included exploring factors influencing vaccination acceptance, examining C-19 vax side effects, and assessing its impact on clinical outcomes in ca pts.
Of 170 pts (males: 82, 48.2%; females: 88, 51.8%), the median age was 65 years. Among them, 58.2% had solid malignancies, 40% had hematologic malignancies, and 1.8% had both. Overall, 146 (85.9%) received the C-19 vax. Among 170 pts, 49 (28.8%) were C-19 positive (C19+), with 9 (18.4%) requiring hospitalization. Prior C19+ pts had a vaccination rate of 73.5% compared to 90.9% in C-19-negative pts(C19–)(P= 0.0013). Demographic factors did not significantly influence vax uptake. Half of the pts experienced vax side effects, but only one (0.68%) reported a treatment delay due to the C-19 vax, and believed that vax affected the ca outcome.
The study found that most ca pts tolerated the C-19 vax well, prior infection decreased uptake, and had no notable effect on ca outcomes.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e18897
Clinical Trial: https://classic.clinicaltrials.gov/ct2/show/NCT04953065
Hyma Vani Polimera, Lauren Danielle Pomerantz, Emma Guare, Junjia Zhu, and Monika Joshi. DOI: 10.1200/JCO.2023.41.16_suppl.e18897 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e18897-e18897.
